19 June 2013
Keywords: enzyme, Manufacturing plant investment, Myozyme, Lumizyme
Article | 21 January 2011
US rare disease drug specialist Genzyme (Nasdaq: GENZ), the subject of a hostile takeover offer from France’s Sanofi-Aventis, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 January 2011
20 January 2011
© 2013 thepharmaletter.com